Does flow cytometric analysis of phospho-p38 mitogen-activated kinase ( MAPK ) : p38 MAPK mediate the effect of adalimumab on peripheral T cell cytokine production in rheumatoid arthritis?
In rheumatoid arthritis, adalimumab therapy decreases the phosphorylation of p38 MAPK except for its response to TNF/IL-1, while enhancing the production of IFNgamma. This suggests that p38 MAPK is not directly involved in the effect of TNF inhibition on cytokine production.
HTX recipients with TPMT genetic variant alleles who are treated with AZA develop acute rejection earlier, more frequently, and of greater severity. These patients, despite having lower TPMT enzymatic activity, should be monitored carefully for possible increased risk of acute rejection.